Kobe C, et al. - In the HD18 trial, positron emission tomography was used after two cycles (PET-2) of eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) in patients with newly diagnosed advanced-stage Hodgkin lymphoma as a guide to further treatment. Researchers evaluated the effect of PET-2 results in the context of eBEACOPP according to the Deauville score (DS) in patients treated in the HD18 trial. Findings showed the association of PET-2 uptake with baseline risk factors large mediastinal mass, extra-nodal disease, and high IPS. In a multivariate analysis including the associated baseline risk factors, the only factor remaining significant for progression-free survival (PFS) was DS4. Overall, based on the findings, DS4 was recommended as the cut-off value for PET-2-positivity.